Opening the Invisible Hand.

Authors: Campbell, Charlie (AUTHOR), Dickstein, Leslie (AUTHOR)

Source: TIME Magazine. 1/27/2025, Vol. 205 Issue 1/2, p48-54. 7p. 7 Color Photographs.

Subjects: NATURAL resources, SINGLE-use plastics, CAUSATION (Philosophy), BUSINESS partnerships, LEAF blowers

Semantic-Enhanced Foundation Model for Coastal Land Use Recognition from Optical Satellite Images.

Authors: Shao, Mengmeng¹, 12112@xzit.edu.cn, Xie, Xiao², xiexiao@iae.ac.cn, Li, Kaiyuan³, kaiyuanli@cumt.edu.cn, Li, Changgui⁴, lichgui@cumt.edu.cn, Zhou, Xiran³, xrzhou@cumt.edu.cn

Source: Applied Sciences (2076-3417); Oct2024, Vol. 14 Issue 20, p9431, 19p

18 WAYS TO TRIM YOUR ENERGY BILL.

Authors: BORTZ, DANIEL (AUTHOR) feedback@kiplinger.com

Source: Kiplinger Personal Finance. Oct2024, Vol. 78 Issue 10, p42-47. 6p. 4 Color Photographs, 1 Chart.

Subject Terms: *Tax credits, *Natural gas prices, Russian invasion of Ukraine, 2022-, Home energy use, Inflation Reduction Act of 2022, Renewable energy transition (Government policy), Light bulbs

Plastic Burnout.

Authors: Baker, Aryn (AUTHOR), Movono, Lice (AUTHOR), Dickstein, Leslie (AUTHOR)

Source: TIME Magazine. 7/15/2024, Vol. 204 Issue 1/2, p38-45. 8p. 4 Color Photographs.

Subjects: PLASTICS, SINGLE-use plastics, MASLACH Burnout Inventory, PLASTIC marine debris, INCINERATION, FLUOROALKYL compounds

This result is not displayed to guests.
Login for full access.

Remote Sensing-Enabled Urban Growth Simulation Overlaid with AHP-GIS-Based Urban Land Suitability for Potential Development in Mersin Metropolitan Area, Türkiye.

Authors: Sahin, Ezgi¹, ezgisahin.9600@gmail.com, Iban, Muzaffer Can², caniban@mersin.edu.tr, Bilgilioglu, Suleyman Sefa³, sbilgilioglu@aksaray.edu.tr

Source: Applied Sciences (2076-3417); Apr2024, Vol. 14 Issue 8, p3484, 27p

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

The Role of Diet and Oral Supplementation for the Management of Diabetic Retinopathy and Diabetic Macular Edema: A Narrative Review.

Authors: D'Angelo, Angela¹ (AUTHOR), Lixi, Filippo² (AUTHOR), Vitiello, Livio³ (AUTHOR) livio.vitiello@gmail.com, Gagliardi, Vincenzo³ (AUTHOR), Pellegrino, Alfonso³ (AUTHOR), Giannaccare, Giuseppe² (AUTHOR), Lee, Deokho (AUTHOR) deokho.lee01@gmail.com

Source: BioMed Research International. 2/24/2025, Vol. 2025, p1-21. 21p.

Subject Terms: *PHYTOTHERAPY, *THERAPEUTIC use of zinc, *THERAPEUTIC use of ubiquinones, *VITAMIN therapy, *VASCULAR endothelial growth factors, *HYPERLIPIDEMIA, *DIABETIC retinopathy, *CAROTENOIDS, *FLAVONOIDS, *UNSATURATED fatty acids, *MELATONIN, *MACULAR edema, *HYPERGLYCEMIA, *INSULIN resistance, *REACTIVE oxygen species, *REACTIVE nitrogen species, *LUTEIN, *PLANT extracts, *RESVERATROL, *ZEAXANTHIN, *CURCUMIN, *PROTEOLYTIC enzymes, *DIETARY supplements, *INTERLEUKINS, *TUMOR necrosis factors, *LYCOPENE, *POLYPHENOLS, *LIPOIC acid, *GINKGO

Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer.

Authors: Hirakawa, Tetsu¹ (AUTHOR) bgdwj032@yahoo.co.jp, Yamaguchi, Kakuhiro¹ (AUTHOR) ta-masuda@hiroshima-u.ac.jp, Funaishi, Kunihiko¹ (AUTHOR) tnaka@hiroshima-u.ac.jp, Shimoji, Kiyofumi¹ (AUTHOR) nhattori@hiroshima-u.ac.jp, Sakamoto, Shinjiro¹ (AUTHOR), Horimasu, Yasushi¹ (AUTHOR), Masuda, Takeshi¹ (AUTHOR), Nakashima, Taku¹ (AUTHOR), Iwamoto, Hiroshi¹ (AUTHOR), Hamada, Hironobu² (AUTHOR), Yamada, Shingo³ (AUTHOR), Hattori, Noboru¹ (AUTHOR)

Source: Cancers. Feb2025, Vol. 17 Issue 4, p572. 15p.

Subject Terms: *THERAPEUTIC use of antineoplastic agents, *THERAPEUTIC use of monoclonal antibodies, *VASCULAR endothelial growth factors, *PROTEINS, *PROGRAMMED death-ligand 1, *LOGISTIC regression analysis, *RETROSPECTIVE studies, *DESCRIPTIVE statistics, *MULTIVARIATE analysis, *DRUG efficacy, *LUNG cancer, *PROGRESSION-free survival, *PROPORTIONAL hazards models, *EVALUATION

Compliance with iron-folate supplementation among pregnant women in Southern Ethiopia: a multi-center cross-sectional study.

Authors: Taye, Mirkat¹ mirkattaye@gmail.com, Mohammed, Temesgen² tememohamme@gmail.com, Taye, Wondimagegn² wontayee@gmail.com, Glagn, Mustefa³ mustesami02@gmail.com, Yihune, Manaye^3,4 manayeyih@gmail.com

Source: Reproductive Health. 2/13/2025, Vol. 22 Issue 1, p1-12. 12p.

Subject Terms: *THERAPEUTIC use of iron, *THERAPEUTIC use of folic acid, *IRON in the body, *PATIENT compliance, *CROSS-sectional method, *PREGNANT women, *DESCRIPTIVE statistics, *ODDS ratio, *RESEARCH, *DRUGS, *DATA analysis software, *CONFIDENCE intervals, *DIETARY supplements, *PREGNANCY

Geographic Terms: ETHIOPIA

Spatiotemporal simulation of sustainable development based on ecosystem services under climate change.

Authors: Zhou, Bao^1,2 (AUTHOR), Chen, Guoping² (AUTHOR) chenguoping@kust.edu.cn, Zhao, Junsan² (AUTHOR), Yin, Ying¹ (AUTHOR)

Source: PLoS ONE. 2/4/2025, Vol. 20 Issue 2, p1-19. 19p.

Subject Terms: *LAND use planning, *REGIONAL development, *ECOSYSTEM services, *LAND use, *SUSTAINABLE development

Alterations of Nutrient Elements in Hepatocellular Carcinoma Patients Treated with Atezolizumab-Bevacizumab.

Authors: Xiao, Shuyue^1,2,3,4, Huang, Xiaohui^4,5, Liu, Shuer^4,5, Jin, Di⁴, Liu, Zheng⁴ zliu1111@163.com

Source: Nutrition & Cancer. 2025, Vol. 77 Issue 2, p244-251. 8p.

Subject Terms: *THERAPEUTIC use of antineoplastic agents, *THERAPEUTIC use of monoclonal antibodies, *RESEARCH funding, *CREATININE, *BEVACIZUMAB, *TRACE elements, *ASPARTATE aminotransferase, *ALKALINE phosphatase, *BLOOD urea nitrogen, *CALCIUM, *NUTRITIONAL status, *ALANINE aminotransferase, *HEPATOCELLULAR carcinoma

Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial.

Authors: Oppelt, Peter J.^1,2 (AUTHOR) poppelt@wustl.edu, Puram, Sidharth V.^2,3 (AUTHOR), Liu, Jingxia⁴ (AUTHOR) esther@wustl.edu, Ley, Jessica C.¹ (AUTHOR) jcley@wustl.edu, Adkins, Douglas^1,2 (AUTHOR) dadkins@wustl.edu

Source: Cancers. Feb2025, Vol. 17 Issue 3, p437. 12p.

Subject Terms: *THERAPEUTIC use of antineoplastic agents, *THERAPEUTIC use of monoclonal antibodies, *SQUAMOUS cell carcinoma, *DRUG toxicity, *CANCER relapse, *PATIENT safety, *RESEARCH funding, *HEAD & neck cancer, *CLINICAL trials, *ANTINEOPLASTIC agents, *CANCER patients, *ORAL drug administration, *DRUG dosage, *METASTASIS, *MONOCLONAL antibodies, *INTRAVENOUS therapy, *DRUG efficacy

The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives.

Authors: Takeda, Mitsunobu¹ (AUTHOR) mtakeda@gesurg.med.osaka-u.ac.jp, Yoshida, Shoma¹ (AUTHOR), Inoue, Takuya¹ (AUTHOR), Sekido, Yuki¹ (AUTHOR), Hata, Tsuyoshi¹ (AUTHOR), Hamabe, Atsushi¹ (AUTHOR), Ogino, Takayuki¹ (AUTHOR), Miyoshi, Norikatsu¹ (AUTHOR), Uemura, Mamoru¹ (AUTHOR), Yamamoto, Hirofumi¹ (AUTHOR), Doki, Yuichiro¹ (AUTHOR), Eguchi, Hidetoshi¹ (AUTHOR)

Source: Cancers. Feb2025, Vol. 17 Issue 3, p428. 21p.

Subject Terms: *THERAPEUTIC use of antineoplastic agents, *THERAPEUTIC use of monoclonal antibodies, *DRUG resistance in cancer cells, *CLINICAL trials, *ENZYME inhibitors, *COLORECTAL cancer, *CELLULAR signal transduction, *TREATMENT effectiveness, *SMALL molecules, *GENETIC mutation, *TRANSFERASES, *STEM cells, *DRUG development, *VACCINES

Metabolic Heterogeneity in Diffuse Large B-Cell Lymphoma Cells Reveals an Innovative Antimetabolic Combination Strategy.

Authors: Lordello, Leonardo¹ (AUTHOR) leomelo@gmail.com, Nuan-Aliman, Stéphanie¹ (AUTHOR) stephanie.nuan@gmail.com, Kielbassa-Elkadi, Karoline¹ (AUTHOR) karoline.elkadi@gmail.com, Montagne, Aurélie¹ (AUTHOR) aurelie.montagne@outlook.fr, Kotta, Konstantina¹ (AUTHOR) kn.kotta@gmail.com, Martins, Isabelle^2,3 (AUTHOR) isabellemart@gmail.com, Pinto Jurado, Eva¹ (AUTHOR) pintoj.eva@gmail.com, Caradeuc, Cédric⁴ (AUTHOR) cedric.caradeuc@u-paris.fr, Lehmann-Che, Jacqueline^5,6 (AUTHOR) jacqueline.lehmann-che@aphp.fr, Martínez-Climent, José Ángel⁷ (AUTHOR) jamcliment@unav.es, Meignin, Véronique^1,8 (AUTHOR) veronique.meignin@aphp.fr, Giraud, Nicolas⁴ (AUTHOR) nicolas.giraud@u-paris.fr, Kroemer, Guido^2,3,9 (AUTHOR) kroemer@orange.fr, Bertho, Gildas⁴ (AUTHOR) gildas.bertho@u-paris.fr, Thieblemont, Catherine^1,10 (AUTHOR) catherine.thieblemont@aphp.fr, Baud, Véronique¹ (AUTHOR) veronique.baud@inserm.fr

Source: Cancers. Feb2025, Vol. 17 Issue 3, p394. 19p.

Subject Terms: *THERAPEUTIC use of antineoplastic agents, *THERAPEUTIC use of antimetabolites, *LIPID metabolism, *METFORMIN, *CANCER relapse, *RESEARCH funding, *NUCLEAR magnetic resonance spectroscopy, *GLYCOLYSIS, *ANTINEOPLASTIC agents, *APOPTOSIS, *CANCER patients, *ASPARAGINASE, *METABOLISM, *CELL survival, *B cell lymphoma, *TRICARBOXYLIC acids

Interaction of population density and slope will exacerbate spatiotemporal changes in land use and landscape patterns in mountain city.

Authors: Zhang, Cui-fang¹ (AUTHOR) zhangcuifang0929@163.com, Wang, Ze-yuan¹ (AUTHOR) lcuwangzeyuan@163.com, Wang, Qian¹ (AUTHOR) lcuwangq306@126.com, Yang, Chuan-hao¹ (AUTHOR) yangchuanhao2022@163.com

Source: Scientific Reports. 1/25/2025, Vol. 15 Issue 1, p1-15. 15p.

Subject Terms: *CITIES & towns, *LAND use planning, *LAND use, *LAND resource, *POPULATION density

Initial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center.

Authors: Shionoya, Kento¹ (AUTHOR) kjscf034@tokyo-med.ac.jp, Sofuni, Atsushi^1,2 (AUTHOR) a-sofuni@tokyo-med.ac.jp, Mukai, Shuntaro¹ (AUTHOR) s-mukai@tokyo-med.ac.jp, Yamauchi, Yoshiya¹ (AUTHOR) yoyama@tokyo-med.ac.jp, Tsuchiya, Takayoshi¹ (AUTHOR) tsuchiya@tokyo-med.ac.jp, Tanaka, Reina¹ (AUTHOR) r-tanaka@tokyo-med.ac.jp, Tonozuka, Ryosuke¹ (AUTHOR) tonozuka@tokyo-med.ac.jp, Yamamoto, Kenjiro¹ (AUTHOR) kenjiro@tokyo-med.ac.jp, Nagai, Kazumasa¹ (AUTHOR) kazu4439@tokyo-med.ac.jp, Matsunami, Yukitoshi¹ (AUTHOR) ym1228@tokyo-med.ac.jp, Kojima, Hiroyuki¹ (AUTHOR) kojima-h@tokyo-med.ac.jp, Minami, Hirohito¹ (AUTHOR) minami@tokyo-med.ac.jp, Hirakawa, Noriyuki¹ (AUTHOR) d121037@tokyo-med.ac.jp, Zhan, Qiang^1,3 (AUTHOR) zhanq33@163.com, Itoi, Takao¹ (AUTHOR) itoi@tokyo-med.ac.jp

Source: Cancers. Jan2025, Vol. 17 Issue 2, p314. 15p.

Subject Terms: *THERAPEUTIC use of antineoplastic agents, *THERAPEUTIC use of monoclonal antibodies, *CISPLATIN, *ANTINEOPLASTIC agents, *TREATMENT effectiveness, *RETROSPECTIVE studies, *CANCER chemotherapy, *GEMCITABINE, *DRUG efficacy, *MEDICAL records, *ACQUISITION of data, *MEDICAL drainage, *SURVIVAL analysis (Biometry), *PROGRESSION-free survival, *OVERALL survival, BILE duct tumors

Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib.

Authors: Terashima, Takeshi¹ (AUTHOR) tera20jp@gmail.com, Kido, Hidenori¹ (AUTHOR), Takata, Noboru¹ (AUTHOR), Hayashi, Tomoyuki¹ (AUTHOR), Seki, Akihiro¹ (AUTHOR), Nakagawa, Hidetoshi¹ (AUTHOR), Nio, Kouki¹ (AUTHOR), Toyama, Tadashi² (AUTHOR), Iida, Noriho¹ (AUTHOR), Yamada, Shinya¹ (AUTHOR), Shimakami, Tetsuro¹ (AUTHOR), Takatori, Hajime¹ (AUTHOR), Arai, Kuniaki¹ (AUTHOR), Yamashita, Tatsuya¹ (AUTHOR), Mizukoshi, Eishiro¹ (AUTHOR), Yamashita, Taro¹ (AUTHOR)

Source: Cancers. Jan2025, Vol. 17 Issue 2, p278. 12p.

Subject Terms: *THERAPEUTIC use of antineoplastic agents, *THERAPEUTIC use of monoclonal antibodies, *PROTEIN kinase inhibitors, *PATIENT safety, *BEVACIZUMAB, *CLINICAL trials, *DRUG efficacy, *HEPATOCELLULAR carcinoma

Geographic Terms: JAPAN

Efficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC.

Authors: Hosui, Atsushi¹ (AUTHOR) hosui@osakah.johas.go.jp, Hayata, Naoko¹ (AUTHOR), Kurahashi, Tomohide¹ (AUTHOR), Namiki, Akane¹ (AUTHOR), Okamoto, Akino¹ (AUTHOR), Aochi, Kazuki¹ (AUTHOR), Ashida, Munehiro¹ (AUTHOR), Tanimoto, Takafumi¹ (AUTHOR), Murai, Hiroki¹ (AUTHOR), Ohnishi, Kohsaku¹ (AUTHOR), Hirao, Motohiro¹ (AUTHOR), Yamada, Takuya¹ (AUTHOR), Hiramatsu, Naoki¹ (AUTHOR)

Source: Cancers. Jan2025, Vol. 17 Issue 2, p185. 11p.

Subject Terms: *THERAPEUTIC use of antineoplastic agents, *THERAPEUTIC use of monoclonal antibodies, *BEVACIZUMAB, *CHEMOEMBOLIZATION, *CLINICAL trials, *RADIO frequency therapy, *TREATMENT effectiveness, *COMBINED modality therapy, *CATHETER ablation, *HEPATOCELLULAR carcinoma, *OVERALL survival

Geographic Terms: UNITED States